Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0N85H)

• Drug Name: Vidarabine Drug Info
• Synonyms: Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine

Indication

Disease Entry	ICD 11	Status	REF
Hepatosplenic T-cell lymphoma		Approved	[1]
Herpes simplex infection	1F00	Approved	[1]
Herpes simplex virus infection	1F00	Approved	[2]
Herpetic keratitis	1F00.10	Approved	[1]
Immunodeficiency	4A00-4A85	Approved	[1]
Large granular lymphocytic leukemia	2A90.1	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
MALT lymphoma		Approved	[1]
Myeloproliferative neoplasm	2A20	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified		Approved	[1]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[1]
Small intestine lymphoma		Approved	[1]
Splenic marginal zone lymphoma		Approved	[1]
Testicular lymphoma		Approved	[1]
Colon cancer	2B90.Z	Investigative	[1]
Gastric cancer	2B72	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Antiviral Agents
• Cross-matching ID:
  PubChem CID: 21704
  ChEBI ID: CHEBI:45327
  CAS Number: CAS 5536-17-4
  TTD Drug ID: DM0N85H

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[3]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[5]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[6]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[7]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[8]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[9]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[10]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[11]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[8]
PF-1913539	DMXEU14	Alzheimer disease	8A20	Discontinued in Phase 3	[12]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[4]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[13]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[14]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[15]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[4]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[4]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[4]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[16]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Modulator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[4]

References

• [1] Vidarabine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4806).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [5] Clinical pipeline report, company report or official report of Klus Pharma
• [6] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [7] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [10] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [11] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [12] Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
• [13] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [14] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [15] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [16] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [17] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [18] Stable cellular models of nuclear receptor PXR for high-throughput evaluation of small molecules. Toxicol In Vitro. 2018 Oct;52:222-234.